Alternatively, several large clinical trials of EPO performed to assess potential utility of normalizing the marginally low hemoglobin concentrations in patients with breast or head and neck cancers unexpectedly found an increase in mortality within the EPO arm due to tumor progression or significant thrombosis [93-95]. The gene discussed is EPO; the disease is neoplasm.